Bioengineered Mesenchymal Stem/Stromal Cells in Anti-Cancer Therapy: Current Trends and Future Prospects

Bibliographic References

• Pittenger, (1999), Science, 284, pp. 143, 10.1126/science.284.5411.143
• Uccelli, (2008), Nat. Rev. Immunol., 8, pp. 726, 10.1038/nri2395
• Friedenstein, (1970), Cell Tissue Kinet., 3, pp. 393
• Mattar, (2015), Front. Immunol., 6, pp. 560, 10.3389/fimmu.2015.00560
• Puissant, (2005), Br. J. Haematol., 129, pp. 118, 10.1111/j.1365-2141.2005.05409.x
• Bueno, (2011), Int. Endod. J., 44, pp. 800, 10.1111/j.1365-2591.2011.01877.x
• Stappenbeck, (2009), Science, 324, pp. 1666, 10.1126/science.1172687
• Oviedo, (2010), Exp. Cell Res., 316, pp. 3109, 10.1016/j.yexcr.2010.08.008
• Salgado, (2010), Curr. Stem Cell Res. Ther., 5, pp. 103, 10.2174/157488810791268564
• Tian, R., Su, S., Yu, Y., Liang, S., Ma, C., Jiao, Y., Xing, W., Tian, Z., Jiang, T., and Wang, J. (2024). Revolutionizing osteoarthritis treatment: How mesenchymal stem cells hold the key. Biomed. Pharmacother., 173.
• Rasmusson, (2004), Lancet, 363, pp. 1439, 10.1016/S0140-6736(04)16104-7
• Vincent, (2024), Physiol. Rev., 104, pp. 659, 10.1152/physrev.00009.2023
• Zhu, (2009), Leukemia, 23, pp. 925, 10.1038/leu.2008.384
• Qiao, (2008), Cell Res., 18, pp. 500, 10.1038/cr.2008.40
• Otsu, (2009), Blood, 113, pp. 4197, 10.1182/blood-2008-09-176198
• Francois, (2019), Stem Cells Transl. Med., 8, pp. 285, 10.1002/sctm.18-0117
• Huang, (2013), Cancer Gene Ther., 20, pp. 308, 10.1038/cgt.2013.22
• Beckermann, (2008), Br. J. Cancer, 99, pp. 622, 10.1038/sj.bjc.6604508
• Poggi, (2018), Front. Immunol., 9, pp. 262, 10.3389/fimmu.2018.00262
• Karnoub, (2007), Nature, 449, pp. 557, 10.1038/nature06188
• Luo, (2014), Oncogene, 33, pp. 2768, 10.1038/onc.2013.233
• Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., and Gasque, P. (2023). The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential. Int. J. Mol. Sci., 24.
• Papait, A., Stefani, F.R., Cargnoni, A., Magatti, M., Parolini, O., and Silini, A.R. (2020). The Multifaceted Roles of MSCs in the Tumor Microenvironment: Interactions With Immune Cells and Exploitation for Therapy. Front. Cell Dev. Biol., 8.
• Ridge, (2017), Mol. Cancer, 16, pp. 31, 10.1186/s12943-017-0597-8
• Kidd, (2009), Stem Cells, 27, pp. 2614, 10.1002/stem.187
• Quante, (2011), Cancer Cell, 19, pp. 257, 10.1016/j.ccr.2011.01.020
• Taheri, (2024), Med. Res. Rev., 44, pp. 1596, 10.1002/med.22023
• Taeb, S., Rostamzadeh, D., Amini, S.M., Rahmati, M., Golshekan, M., Abedinzadeh, M., Ahmadi, E., Neha, S., and Najafi, M. (2024). Revolutionizing Cancer Treatment: Harnessing the Power of Mesenchymal Stem Cells for Precise Targeted Therapy in the Tumor Microenvironment. Curr. Top. Med. Chem.
• Han, (2022), Signal Transduct. Target. Ther., 7, pp. 92, 10.1038/s41392-022-00932-0
• Chen, (2019), Nat. Reviews. Drug Discov., 18, pp. 99, 10.1038/s41573-018-0004-1
• Ma, (2015), Cell Transplant., 24, pp. 2585, 10.3727/096368915X687462
• Xie, (2017), Stem Cells Transl. Med., 6, pp. 1120, 10.1002/sctm.16-0204
• Smith, (2015), Stem Cells Transl. Med., 4, pp. 239, 10.5966/sctm.2014-0149
• Rattigan, (2010), Exp. Cell Res., 316, pp. 3417, 10.1016/j.yexcr.2010.07.002
• Ringe, (2007), J. Cell. Biochem., 101, pp. 135, 10.1002/jcb.21172
• Schar, (2015), Clin. Orthop. Relat. Res., 473, pp. 1635, 10.1007/s11999-015-4192-2
• Kalimuthu, (2017), Stem Cells Int., 2017, pp. 8085637, 10.1155/2017/8085637
• Kidd, S., Spaeth, E., Watson, K., Burks, J., Lu, H., Klopp, A., Andreeff, M., and Marini, F.C. (2012). Origins of the tumor microenvironment: Quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS ONE, 7.
• Housman, (2014), Cancers, 6, pp. 1769, 10.3390/cancers6031769
• Christodoulou, (2018), Stem Cell Res. Ther., 9, pp. 336, 10.1186/s13287-018-1078-8
• Kraitchman, (2005), Circulation, 112, pp. 1451, 10.1161/CIRCULATIONAHA.105.537480
• Barbash, (2003), Circulation, 108, pp. 863, 10.1161/01.CIR.0000084828.50310.6A
• Kean, (2013), Stem Cells Int., 2013, pp. 732742, 10.1155/2013/732742
• Garcia-Bernal, D., Garcia-Arranz, M., Yanez, R.M., Hervas-Salcedo, R., Cortes, A., Fernandez-Garcia, M., Hernando-Rodriguez, M., Quintana-Bustamante, O., Bueren, J.A., and Garcia-Olmo, D. (2021). The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy. Front. Cell Dev. Biol., 9.
• Bai, (2017), J. Cell. Mol. Med., 21, pp. 2077, 10.1111/jcmm.13131
• Lazennec, (2016), Biochim. Biophys. Acta, 1866, pp. 290
• Li, (2019), J. Neuropathol. Exp. Neurol., 78, pp. 315, 10.1093/jnen/nlz016
• Magne, (2020), J. Investig. Dermatol., 140, pp. 688, 10.1016/j.jid.2019.07.721
• Tsai, (2011), Stroke, 42, pp. 2932, 10.1161/STROKEAHA.110.612788
• Yu, (2011), Mol. Med. Rep., 4, pp. 31
• Najafi, (2013), Expert Opin. Biol. Ther., 13, pp. 959, 10.1517/14712598.2013.782390
• Zheng, (2019), Gastroenterol. Rep., 7, pp. 127, 10.1093/gastro/goy017
• Shao, (2019), Biomed. Pharmacother., 109, pp. 1233, 10.1016/j.biopha.2018.10.108
• Kumar, (2007), FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol., 21, pp. 3917
• Levy, (2013), Blood, 122, pp. e23, 10.1182/blood-2013-04-495119
• Bueren, (2023), Front. Immunol., 14, pp. 1062086, 10.3389/fimmu.2023.1062086
• Sackstein, (2008), Nat. Med., 14, pp. 181, 10.1038/nm1703
• Blanquer, (2022), NPJ Regen. Med., 7, pp. 61, 10.1038/s41536-022-00258-z
• Garcia-Bernal, D., Garcia-Arranz, M., Garcia-Guillen, A.I., Garcia-Hernandez, A.M., Blanquer, M., Garcia-Olmo, D., Sackstein, R., Moraleda, J.M., and Zapata, A.G. (2020). Exofucosylation of Adipose Mesenchymal Stromal Cells Alters Their Secretome Profile. Front. Cell Dev. Biol., 8.
• Sarkar, (2008), Bioconjugate Chem., 19, pp. 2105, 10.1021/bc800345q
• Cheng, (2012), Biomaterials, 33, pp. 5004, 10.1016/j.biomaterials.2012.03.065
• Lo, (2013), Biomaterials, 34, pp. 8213, 10.1016/j.biomaterials.2013.07.033
• Won, (2014), Biomaterials, 35, pp. 5627, 10.1016/j.biomaterials.2014.03.070
• Abels, (2016), Cell. Mol. Neurobiol., 36, pp. 301, 10.1007/s10571-016-0366-z
• Bui, (2018), Tissue Barriers, 6, pp. e1431038, 10.1080/21688370.2018.1431038
• Mendt, (2019), Bone Marrow Transplant., 54, pp. 789, 10.1038/s41409-019-0616-z
• Parolini, (2009), J. Biol. Chem., 284, pp. 34211, 10.1074/jbc.M109.041152
• Zhu, (2012), Cancer Lett., 315, pp. 28, 10.1016/j.canlet.2011.10.002
• Weng, (2021), J. Hematol. Oncol., 14, pp. 136, 10.1186/s13045-021-01141-y
• Dong, (2018), Cell Death Dis., 9, pp. 218, 10.1038/s41419-018-0323-5
• Ren, (2019), J. Exp. Clin. Cancer Res. CR, 38, pp. 62, 10.1186/s13046-019-1027-0
• Casson, (2018), J. Tissue Eng., 9, pp. 2041731418810093, 10.1177/2041731418810093
• Ji, (2015), Cell Cycle, 14, pp. 2473, 10.1080/15384101.2015.1005530
• Ono, (2014), Sci. Signal., 7, pp. ra63, 10.1126/scisignal.2005231
• Wu, S., Ju, G.Q., Du, T., Zhu, Y.J., and Liu, G.H. (2013). Microvesicles derived from human umbilical cord Wharton’s jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo. PLoS ONE, 8.
• Zhang, (2020), Cancer Lett., 490, pp. 54, 10.1016/j.canlet.2020.07.008
• Pakravan, (2017), Cell. Oncol., 40, pp. 457, 10.1007/s13402-017-0335-7
• Herrmann, (2021), Nat. Nanotechnol., 16, pp. 748, 10.1038/s41565-021-00931-2
• Walker, (2019), Theranostics, 9, pp. 8001, 10.7150/thno.37097
• Haney, (2019), Adv. Healthc. Mater., 8, pp. e1801271, 10.1002/adhm.201801271
• Fuhrmann, (2015), J. Control. Release Off. J. Control. Release Soc., 205, pp. 35, 10.1016/j.jconrel.2014.11.029
• Cho, (2013), Materials, 6, pp. 3294, 10.3390/ma6083294
• Cocce, (2017), Sci. Rep., 7, pp. 9376, 10.1038/s41598-017-09175-4
• Abas, B.I., Demirbolat, G.M., and Cevik, O. (2022). Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel. PLoS ONE, 17.
• Hamilton, (2022), Expert Opin. Biol. Ther., 22, pp. 67, 10.1080/14712598.2021.1954156
• Song, (2023), Front. Oncol., 13, pp. 1299384, 10.3389/fonc.2023.1299384
• Munoz, (2013), Mol. Ther. Nucleic Acids, 2, pp. e126, 10.1038/mtna.2013.60
• Katakowski, (2013), Cancer Lett., 335, pp. 201, 10.1016/j.canlet.2013.02.019
• Lee, (2013), Oncotarget, 4, pp. 346, 10.18632/oncotarget.868
• Lou, (2015), J. Hematol. Oncol., 8, pp. 122, 10.1186/s13045-015-0220-7
• Lang, (2018), Neuro-oncology, 20, pp. 380, 10.1093/neuonc/nox152
• Roccaro, (2013), J. Clin. Investig., 123, pp. 1542, 10.1172/JCI66517
• Yuan, (2017), J. Extracell. Vesicles, 6, pp. 1265291, 10.1080/20013078.2017.1265291
• Ye, (2018), ACS Appl. Mater. Interfaces, 10, pp. 12341, 10.1021/acsami.7b18135
• Bagheri, (2020), Life Sci., 261, pp. 118369, 10.1016/j.lfs.2020.118369
• Dembinski, (2013), Cytotherapy, 15, pp. 20, 10.1016/j.jcyt.2012.10.003
• Zischek, (2009), Ann. Surg., 250, pp. 747, 10.1097/SLA.0b013e3181bd62d0
• Shams, F., Pourjabbar, B., Hashemi, N., Farahmandian, N., Golchin, A., Nuoroozi, G., and Rahimpour, A. (2023). Current progress in engineered and nano-engineered mesenchymal stem cells for cancer: From mechanisms to therapy. Biomed. Pharmacother., 167.
• Bonomi, (2017), Hematol. Oncol., 35, pp. 693, 10.1002/hon.2306
• Pessina, A., Bonomi, A., Cocce, V., Invernici, G., Navone, S., Cavicchini, L., Sisto, F., Ferrari, M., Vigano, L., and Locatelli, A. (2011). Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS ONE, 6.
• Babajani, A., Soltani, P., Jamshidi, E., Farjoo, M.H., and Niknejad, H. (2020). Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer. Front. Bioeng. Biotechnol., 8.
• Taeb, (2024), Curr. Mol. Med., 24, pp. 98, 10.2174/1566524023666221226143814
• Alemany, (2010), Cancer Gene Ther., 17, pp. 476, 10.1038/cgt.2010.4
• Hmadcha, A., Martin-Montalvo, A., Gauthier, B.R., Soria, B., and Capilla-Gonzalez, V. (2020). Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy. Front. Bioeng. Biotechnol., 8.
• Lan, (2021), J. Hematol. Oncol., 14, pp. 195, 10.1186/s13045-021-01208-w
• Zhao, (2017), Sci. Rep., 7, pp. 44758, 10.1038/srep44758
• Petrella, (2017), Biomed. Pharmacother., 87, pp. 755, 10.1016/j.biopha.2017.01.118
• Clavreul, (2017), J. Exp. Clin. Cancer Res. CR, 36, pp. 135, 10.1186/s13046-017-0605-2
• Rimoldi, (2018), Biomed. Pharmacother., 108, pp. 111, 10.1016/j.biopha.2018.09.040
• Pacioni, (2017), Stem Cell Res. Ther., 8, pp. 53, 10.1186/s13287-017-0516-3
• Brini, (2016), Expert Opin. Drug Deliv., 13, pp. 789, 10.1517/17425247.2016.1167037
• Hung, (2015), Cancer Lett., 359, pp. 233, 10.1016/j.canlet.2015.01.017
• Bosco, D.B., Kenworthy, R., Zorio, D.A., and Sang, Q.X. (2015). Human mesenchymal stem cells are resistant to Paclitaxel by adopting a non-proliferative fibroblastic state. PLoS ONE, 10.
• Wang, (2019), Acta Pharm. Sin. B, 9, pp. 167, 10.1016/j.apsb.2018.08.006
• Kalimuthu, (2018), Front. Pharmacol., 9, pp. 1116, 10.3389/fphar.2018.01116
• Vizoso, F.J., Eiro, N., Cid, S., Schneider, J., and Perez-Fernandez, R. (2017). Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine. Int. J. Mol. Sci., 18.
• Bonomi, (2015), Cytotherapy, 17, pp. 1687, 10.1016/j.jcyt.2015.09.005
• Pessina, (2013), Br. J. Haematol., 160, pp. 766, 10.1111/bjh.12196
• Golinelli, (2020), Front. Pharmacol., 11, pp. 529921, 10.3389/fphar.2020.529921
• Studeny, (2002), Cancer Res., 62, pp. 3603
• Mueller, (2011), Cancer Gene Ther., 18, pp. 229, 10.1038/cgt.2010.68
• Nakamura, (2004), Gene Ther., 11, pp. 1155, 10.1038/sj.gt.3302276
• Chen, (2008), Mol. Ther. J. Am. Soc. Gene Ther., 16, pp. 749, 10.1038/mt.2008.3
• Ryu, (2011), Hum. Gene Ther., 22, pp. 733, 10.1089/hum.2010.187
• Jing, (2014), Mol. Cancer Ther., 13, pp. 2127, 10.1158/1535-7163.MCT-14-0175
• Sun, (2014), Int. J. Mol. Sci., 15, pp. 3729, 10.3390/ijms15033729
• Tang, (2014), Anticancer Res., 34, pp. 729
• Ren, (2008), Stem Cells, 26, pp. 2332, 10.1634/stemcells.2008-0084
• Li, (2006), Hematol. Oncol., 24, pp. 151, 10.1002/hon.779
• Zhao, (2020), J. Cancer, 11, pp. 5345, 10.7150/jca.38062
• Kim, (2015), Stem Cells Dev., 24, pp. 2808, 10.1089/scd.2015.0103
• Takayama, (2021), Expert Opin. Drug Deliv., 18, pp. 1627, 10.1080/17425247.2021.1960309
• Kim, (2014), Stem Cells Transl. Med., 3, pp. 172, 10.5966/sctm.2013-0132
• Yan, (2013), Mol. Pharm., 10, pp. 142, 10.1021/mp300261e
• Yang, P.M., Hsieh, Y.Y., Du, J.L., Yen, S.C., and Hung, C.F. (2020). Sequential Interferon beta-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner. Biomolecules, 10.
• Yang, (2014), Cancer Cell, 25, pp. 37, 10.1016/j.ccr.2013.12.004
• Xu, (2015), Oncol. Rep., 34, pp. 1915, 10.3892/or.2015.4174
• Mirlekar, B., and Pylayeva-Gupta, Y. (2021). IL-12 Family Cytokines in Cancer and Immunotherapy. Cancers, 13.
• Gao, (2010), Cancer Lett., 290, pp. 157, 10.1016/j.canlet.2009.08.031
• Chen, (2018), Cell Cycle, 17, pp. 858, 10.1080/15384101.2018.1442624
• Musso, (2014), Haematologica, 99, pp. 131, 10.3324/haematol.2013.097311
• Kanehira, (2007), Cancer Gene Ther., 14, pp. 894, 10.1038/sj.cgt.7701079
• Choi, (2015), Mol. Ther. J. Am. Soc. Gene Ther., 23, pp. 235, 10.1038/mt.2014.214
• Mangraviti, (2016), Biomaterials, 100, pp. 53, 10.1016/j.biomaterials.2016.05.025
• Guo, (2016), Oncotarget, 7, pp. 55529, 10.18632/oncotarget.10835
• Guo, (2016), Oncol. Lett., 11, pp. 2733, 10.3892/ol.2016.4297
• Asija, (2023), Front. Immunol., 14, pp. 1118246, 10.3389/fimmu.2023.1118246
• Zheng, (2019), Mol. Ther. Oncolytics, 15, pp. 234, 10.1016/j.omto.2019.10.007
• Hemminki, (2020), J. Hematol. Oncol., 13, pp. 84, 10.1186/s13045-020-00922-1
• Moreno, (2021), J. Immunother. Cancer, 9, pp. e001684, 10.1136/jitc-2020-001684
• Kaufman, (2015), Nat. Rev. Drug Discov., 14, pp. 642, 10.1038/nrd4663
• Reale, A., Calistri, A., and Altomonte, J. (2021). Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy. Pharmaceutics, 13.
• Hadrys, (2020), Eur. J. Pharmacol., 874, pp. 172991, 10.1016/j.ejphar.2020.172991
• Ruano, (2020), Mol. Ther. J. Am. Soc. Gene Ther., 28, pp. 1033, 10.1016/j.ymthe.2020.01.019
• Chulpanova, (2018), Front. Pharmacol., 9, pp. 259, 10.3389/fphar.2018.00259
• Liang, W., Chen, X., Zhang, S., Fang, J., Chen, M., and Xu, Y. (2021). Mesenchymal stem cells as a double-edged sword in tumor growth: Focusing on MSC-derived cytokines. Cell Mol. Biol. Lett., 26.
• Gambera, (2018), Cancer Immunol. Immunother. CII, 67, pp. 1589, 10.1007/s00262-018-2220-2
• Gambera, (2021), J. Immunother. Cancer, 9, pp. e001703, 10.1136/jitc-2020-001703
• Rincon, (2017), Oncotarget, 8, pp. 45415, 10.18632/oncotarget.17557
• Hoyos, (2015), Mol. Ther. J. Am. Soc. Gene Ther., 23, pp. 1497, 10.1038/mt.2015.110
• Moreno, (2017), Stem Cells Int., 2017, pp. 3615729, 10.1155/2017/3615729
• Moreno, (2019), Mol. Cancer Ther., 18, pp. 127, 10.1158/1535-7163.MCT-18-0431
• Barlabe, (2020), Cancer Gene Ther., 27, pp. 383, 10.1038/s41417-019-0110-1
• He, (2015), Mol. Ther. J. Am. Soc. Gene Ther., 23, pp. 108, 10.1038/mt.2014.204
• Cejalvo, (2018), Cancer Res., 78, pp. 4891, 10.1158/0008-5472.CAN-17-3754
• Delgado-Bonet, P., Tomeo-Martin, B.D., Ortiz-Diez, G., and Perise-Barrios, A.J. (2022). Tumor-Homing of Mesenchymal Stem Cells Infected with Oncolytic Virus in a Canine Patient. Vet. Sci., 9.
• Hsiao, (2012), Mol. Pharm., 9, pp. 1396, 10.1021/mp200649g
• Na, (2019), J. Control. Release Off. J. Control. Release Soc., 305, pp. 75, 10.1016/j.jconrel.2019.04.040
• Nilson, R., Krutzke, L., Wienen, F., Rojewski, M., Zeplin, P.H., Funk, W., Schrezenmeier, H., Kochanek, S., and Kritzinger, A. (2023). Evaluation of Human Mesenchymal Stromal Cells as Carriers for the Delivery of Oncolytic HAdV-5 to Head and Neck Squamous Cell Carcinomas. Viruses, 15.
• Wang, P., Zhang, J., Zhang, Q., and Liu, F. (2023). Mesenchymal stem cells loaded with Ad5-Ki67/IL-15 enhance oncolytic adenovirotherapy in experimental glioblastoma. Biomed. Pharmacother., 157.
• Hakkarainen, (2007), Hum. Gene Ther., 18, pp. 627, 10.1089/hum.2007.034
• Yuan, (2016), Cancer Lett., 381, pp. 85, 10.1016/j.canlet.2016.07.019
• Hammer, (2015), Int. J. Cancer, 137, pp. 978, 10.1002/ijc.29442
• Komarova, (2006), Mol. Cancer Ther., 5, pp. 755, 10.1158/1535-7163.MCT-05-0334
• Kaczorowski, (2016), Oncotarget, 7, pp. 9046, 10.18632/oncotarget.7031
• Li, (2016), Oncotarget, 7, pp. 51815, 10.18632/oncotarget.10122
• Yoon, (2019), Cancer Res., 79, pp. 4503, 10.1158/0008-5472.CAN-18-3900
• Mahasa, (2020), Sci. Rep., 10, pp. 425, 10.1038/s41598-019-57240-x
• Muhammad, (2019), Stem Cell Res. Ther., 10, pp. 190, 10.1186/s13287-019-1268-z
• Rivera, (2007), Breast Cancer Res. Treat., 105, pp. 157, 10.1007/s10549-006-9449-8
• Ho, C.T., Wu, M.H., Chen, M.J., Lin, S.P., Yen, Y.T., and Hung, S.C. (2021). Combination of Mesenchymal Stem Cell-Delivered Oncolytic Virus with Prodrug Activation Increases Efficacy and Safety of Colorectal Cancer Therapy. Biomedicines, 9.
• Guo, (2019), Stem Cells Dev., 28, pp. 882, 10.1089/scd.2018.0222
• Bolontrade, (2012), Stem Cells Dev., 21, pp. 2689, 10.1089/scd.2011.0643
• Sonabend, (2008), Stem Cells, 26, pp. 831, 10.1634/stemcells.2007-0758
• Ahmed, (2010), Mol. Ther. J. Am. Soc. Gene Ther., 18, pp. 1846, 10.1038/mt.2010.131
• Zhang, (2022), Mol. Ther. Oncolytics, 24, pp. 486, 10.1016/j.omto.2022.01.007
• Dembinski, (2010), Cancer Gene Ther., 17, pp. 289, 10.1038/cgt.2009.67
• Yong, (2009), Cancer Res., 69, pp. 8932, 10.1158/0008-5472.CAN-08-3873
• Shinojima, (2013), Cancer Res., 73, pp. 2333, 10.1158/0008-5472.CAN-12-3086
• Shimizu, (2022), J. Neurosurg., 136, pp. 757, 10.3171/2021.3.JNS203045
• Zhang, (2021), Cancer Lett., 509, pp. 26, 10.1016/j.canlet.2021.03.027
• He, (2023), J. Transl. Med., 21, pp. 688, 10.1186/s12967-023-04539-z
• Du, (2017), Proc. Natl. Acad. Sci. USA, 114, pp. E6157, 10.1073/pnas.1700363114
• Leoni, (2015), Oncotarget, 6, pp. 34774, 10.18632/oncotarget.5793
• Nguyen, D.H., Herrmann, T., Hartl, B., Draganov, D., Minev, I., Neuharth, F., Gomez, A., Alamillo, A., Schneider, L.E., and Kleinholz, D. (2022). Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy. Cancers, 14.
• Petrov, I., Gentschev, I., Vyalkova, A., Elashry, M.I., Klymiuk, M.C., Arnhold, S., and Szalay, A.A. (2020). Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a “Trojan Horse” in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas. Viruses, 12.
• Draganov, (2019), J. Transl. Med., 17, pp. 100, 10.1186/s12967-019-1829-z
• Sochanik, (2020), Mol. Ther. Oncolytics, 18, pp. 335, 10.1016/j.omto.2020.07.003
• Jazowiecka-Rakus, J., Hadrys, A., Rahman, M.M., McFadden, G., Fidyk, W., Chmielik, E., Pazdzior, M., Grajek, M., Kozik, V., and Sochanik, A. (2021). Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma. Cancers, 13.
• Jazowiecka-Rakus, J., Sochanik, A., Hadrys, A., Fidyk, W., Chmielik, E., Rahman, M.M., and McFadden, G. (2022). Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma. Cancers, 14.
• Josiah, (2010), Mol. Ther. J. Am. Soc. Gene Ther., 18, pp. 377, 10.1038/mt.2009.265
• Mader, (2009), Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 15, pp. 7246, 10.1158/1078-0432.CCR-09-1292
• Mader, (2013), J. Transl. Med., 11, pp. 20, 10.1186/1479-5876-11-20
• Ong, (2013), J. Hepatol., 59, pp. 999, 10.1016/j.jhep.2013.07.010
• Castleton, (2014), Blood, 123, pp. 1327, 10.1182/blood-2013-09-528851
• Dorostkar, (2023), Infect. Agents Cancer, 18, pp. 46, 10.1186/s13027-023-00521-y
• Keshavarz, (2020), Virol. J., 17, pp. 64, 10.1186/s12985-020-01326-w
• Kazimirsky, (2016), Stem Cell Res. Ther., 7, pp. 149, 10.1186/s13287-016-0414-0
• Soleimanjahi, (2021), Cancer Cell Int., 21, pp. 244, 10.1186/s12935-021-01848-5
• Babaei, (2021), Adv. Pharm. Bull., 11, pp. 361
• Babaei, A., Soleimanjahi, H., Soleimani, M., and Arefian, E. (2021). Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer. Biochem. Pharmacol., 190.
• Banijamali, (2021), J. Cell. Biochem., 122, pp. 1360, 10.1002/jcb.29955
• Wang, (2021), Oncol. Lett., 21, pp. 238, 10.3892/ol.2021.12499
• Zarogoulidis, (2013), J. Genet. Syndr. Gene Ther., 4, pp. 16849
• Moolten, (1986), Cancer Res., 46, pp. 5276
• Fillat, (2003), Curr. Gene Ther., 3, pp. 13, 10.2174/1566523033347426
• Zhang, (2015), J. Control. Release Off. J. Control. Release Soc., 209, pp. 260, 10.1016/j.jconrel.2015.05.007
• Leng, (2014), Biomaterials, 35, pp. 5162, 10.1016/j.biomaterials.2014.03.014
• Alieva, M., Bago, J.R., Aguilar, E., Soler-Botija, C., Vila, O.F., Molet, J., Gambhir, S.S., Rubio, N., and Blanco, J. (2012). Glioblastoma therapy with cytotoxic mesenchymal stromal cells optimized by bioluminescence imaging of tumor and therapeutic cell response. PLoS ONE, 7.
• Yang, (2019), Cancer Manag. Res., 11, pp. 8443, 10.2147/CMAR.S209880
• Chang, (2020), Am. J. Cancer Res., 10, pp. 1429
• NguyenThai, (2015), J. Gene Med., 17, pp. 87, 10.1002/jgm.2826
• Nowakowski, (2016), Stem Cells Dev., 25, pp. 1513, 10.1089/scd.2016.0120
• Abrate, (2014), Eur. J. Cancer, 50, pp. 2478, 10.1016/j.ejca.2014.06.014
• Kim, (2023), Am. J. Cancer Res., 13, pp. 2439
• Choi, (2012), Eur. J. Cancer, 48, pp. 129, 10.1016/j.ejca.2011.04.033
• Amara, (2016), J. Control. Release Off. J. Control. Release Soc., 239, pp. 82, 10.1016/j.jconrel.2016.08.019
• Yamamoto, (2003), Cancer Gene Ther., 10, pp. 179, 10.1038/sj.cgt.7700551
• Ryu, (2012), Biochem. Biophys. Res. Commun., 421, pp. 585, 10.1016/j.bbrc.2012.04.050
• Sun, (2022), Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 28, pp. 4392, 10.1158/1078-0432.CCR-22-0622
• Duhrsen, (2019), Oncotarget, 10, pp. 6049, 10.18632/oncotarget.27071
• Melen, (2016), Cancer Lett., 371, pp. 161, 10.1016/j.canlet.2015.11.036
• Peter, (2017), Oncotarget, 8, pp. 80156, 10.18632/oncotarget.20964